Literature DB >> 6750227

Studies on host defenses enhanced by endotoxins: a brief review.

A Nowotny, U H Behling.   

Abstract

The findings reported here indicate that toxic reactions to endotoxin do not have to be part of the mechanisms leading to clinically improved status of patients or of experimental animals. It seems to be possible to mobilize the host defenses without the unwanted or dangerous side effects which were encountered during fever therapy. For the demonstration of activated host defenses, several experimental models are available. Non-specific resistance to bacterial infections, to lethal irradiation or to experimental challenge with viable tumors are clear manifestations of enhanced capacity of the endotoxin-treated host to compensate for the induced damage, or to cope with an otherwise overwhelming number of pathogenic cells. Immunopotentiation is obviously one of the contributing factors in some of the above parameters. How these results are applicable to human therapy remains to be seen. Such use of endotoxin derivatives, or better, the mediators of beneficial endotoxic effects, must wait until we learn more about the nature of the alternating positive and negative effects of endotoxin application. The importance of the proper timing of such a therapeutic modality cannot be overemphasized.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6750227     DOI: 10.1007/bf01716566

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  53 in total

1.  [Recent research on the chemistry and biology of the endotoxins of gram-negative bacteria].

Authors:  O WESTPHAL
Journal:  Ann Inst Pasteur (Paris)       Date:  1960-06

2.  Increased survival in irradiated animals treated with bacterial endotoxins.

Authors:  W W SMITH; I M ALDERMAN; R E GILLESPIE
Journal:  Am J Physiol       Date:  1957-10

3.  Quantitative study of the granulopectic activity of the reticulo-endothelial system. I. The effect of the ingredients present in India ink and of substances affecting blood clotting in vivo on the fate of carbon particles administered intravenously in rats, mice and rabbits.

Authors:  B N HALPERN; B BENACERRAF; G BIOZZI
Journal:  Br J Exp Pathol       Date:  1953-08

4.  The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research.

Authors:  H C NAUTS; W E SWIFT; B L COLEY
Journal:  Cancer Res       Date:  1946-04       Impact factor: 12.701

5.  Pyrogens in the treatment of malignant hypertension.

Authors:  I H PAGE; R D TAYLOR
Journal:  Mod Concepts Cardiovasc Dis       Date:  1949-10

6.  Clinical evaluation of a new pyrogenic agent.

Authors:  R R KIERLAND; M H KULWIN
Journal:  AMA Arch Derm Syphilol       Date:  1950-10

7.  Long-term adjuvant effect of bacterial endotoxin in prevention and restoration of radiation-caused immunosuppression.

Authors:  U H Behling; A Nowotny
Journal:  Proc Soc Exp Biol Med       Date:  1978-03

8.  Bone marrow colony-stimulating factor and tumor resistance-enhancing activity of postendotoxin mouse sera.

Authors:  R C Butler; A M Abdelnoor; A Nowotny
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

9.  Immunocycte stimulation in vitro by nontoxic bacterial lipopolysaccharide derivatives.

Authors:  S Frank; S Specter; A Nowotny; H Friedman
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

10.  Enhancement of resistance to infections by endotoxin-induced serum factor from Mycobacterium bovis BCG-infected mice.

Authors:  M A Parant; F J Parant; L A Chedid
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.